Guided Poster Tour 3 - Pediatric Treatment and Care - HIV Pediatrics 2021

International Workshop on HIV Pediatrics 2021

Guided Poster Tour 2 - Pregnancy and HIV - HIV Pediatrics 2021

International Workshop on HIV Pediatrics 2021

Guided Poster Tour 1 - Prevention of Perinatal HIV Transmission - HIV Pediatrics 2021

International Workshop on HIV Pediatrics 2021

Guided Poster Tour 1 - Prevention of Perinatal HIV Transmission - HIV Pediatrics 2021

International Workshop on HIV Pediatrics 2021

Session 3 - Clinical Case Presentations - HIV Pediatrics 2021

International Workshop on HIV Pediatrics 2021

Knowledge and Perceptions of Covid-19 Among Young People Living With HIV in Malawi and the Impact of the Pandemic on Their Health and Wellbeing - Kajal Hirani, Malawi

International Workshop on HIV Pediatrics 2021

Pediatric and Adolescent HIV Viral Load Coverage and Suppression Rates in the Context of the COVID-19 Pandemic in 14 Sub-Saharan African PEPFAR Countries in 2019 and 2020 - Deborah Carpenter, United States

International Workshop on HIV Pediatrics 2021

The Impact of COVID-19 on HIV Services for Children Living with HIV Across 14 Countries - Megan Gleason, United States

International Workshop on HIV Pediatrics 2021

Early Infant Diagnosis of HIV and Linkage to Antiretroviral Therapy in the Context of COVID-19 in Fifteen Sub-Saharan African Countries - Elizabeth Rabold, United States

International Workshop on HIV Pediatrics 2021

A Comparative Multi-Country Analysis of the Impact of COVID-19 on HIV Services for Pregnant and Breastfeeding Women and Their Infants - Alexandra Vrazo, United States

International Workshop on HIV Pediatrics 2021

Impact of the COVID-19 Pandemic on Perinatal HIV Prevention in Canada: Canadian Perinatal HIV Surveillance Program - Joel Singer, Canada

International Workshop on HIV Pediatrics 2021

Bone Mineral Density/Content of Postpartum Mothers Taking Treatment Including DTG Vs EFV, TDF Vs TAF in Pregnancy and Their Infants: Randomized IMPAACT 2010 Trial - Tapiwa Mbengeranwa, Zimbabwe

International Workshop on HIV Pediatrics 2021

Hypertensive Disorders in Pregnancy and HIV: A Province-Wide Cohort Analysis During 2018 and 2019 in the Western Cape, South Africa - Amy Slogrove, South Africa

International Workshop on HIV Pediatrics 2021

Virological Failures and Genotypic Resistance in Children and Adolescents Randomised to Dolutegravir-Based ART vs. Standard-of- Care in the ODYSSEY Trial - Cissy Kityo, Uganda

International Workshop on HIV Pediatrics 2021

Longitudinal Study on Insulin Resistance and Metabolic Syndrome in Children with Perinatal HIV Infection and HIV Exposed Uninfected Children in South Africa - Claire Davies, South Africa

International Workshop on HIV Pediatrics 2021

Dolutegravir and Weight Gain to Adolescents Living with HIV at Baylor Mwanza-Tanzania - Esther Masunga, Tanzania

International Workshop on HIV Pediatrics 2021

Weight Gain in Children and Adolescents on Dolutegravir vs Standard-of-Care in the ODYSSEY Trial - Hilda Angela Mujuru, Zimbabwe

International Workshop on HIV Pediatrics 2021

LATE BREAKER - Dolutegravir-Based Art is Superior to Standard of Care in Young Children Living With HIV - Pauline Amuge, Uganda

International Workshop on HIV Pediatrics 2021

Clinical Impact and Cost-Effectiveness of Viral Load Testing (VLT) to Inform the Transition to Pediatric Dolutegravir (DTG) in Antiretroviral Therapy (ART)-Experienced Children With HIV in South Africa - Isaac Ravi Brenner, United States

International Workshop on HIV Pediatrics 2021

Pharmacokinetics, Safety and Acceptability of a Single Dose of Abacavir/Lamivudine/Lopinavir/Ritonavir (4-In-1) Fixed-Dose Granule Formulation In Neonates: PETITE Study - Tim Cressey, Thailand

International Workshop on HIV Pediatrics 2021

Long-Term Safety & Efficacy of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide Fumarate (E/C/F/TAF) Single-Tablet Regimen In Children and Adolescents Living With HIV - Suvaporn Anugulruengkitt, Thailand

International Workshop on HIV Pediatrics 2021

Pharmacokinetics and Safety of Dispersible- and Immediate-Release FDC Dolutegravir/Abacavir/Lamivudine in Children with HIV Weighing ≥14 Kg: Preliminary Results from IMPAACT 2019 - Kristina Brooks, United States

International Workshop on HIV Pediatrics 2021

B/F/Taf in Virologically Suppressed Adolescents and Children: Two- Year Outcomes in 6 to <18 Year Olds And Six-Month Outcomes in Toddlers - Eva Natukunda, Uganda

International Workshop on HIV Pediatrics 2021

Once-Daily Integrase Inhibitor (Insti) With Boosted Darunavir is Non- Inferior to Standard of Care in Virogically Suppressed Children, Week 48 Results of the Smile PENTA-17 Trial - Alexandra Compagnucci, France

International Workshop on HIV Pediatrics 2021